Proteomic-based analysis for identification of proteins involved in 5-fluorouracil resistance in hepatocellular carcinoma

Current Pharmaceutical Design

Volumn 20, Issue 1, 2014, Pages 81-87

  Tan, Yi ^a   Qin, Shukui ^b   Hou, Xin ^a   Qian, Xiujuan ^a   Xia, Jun ^a   Li, Yumei ^a   Wang, Rui ^a   Chen, Changjie ^a   Yang, Qingling ^a   Miele, Lucio ^c   Wu, Qiong ^a   Wang, Zhiwei ^d,e  

^a BENGBU MEDICAL COLLEGE   (China)

^b Nanjing Bayi Hospital   (China)

^c UNIVERSITY OF MISSISSIPPI   (United States)

^d SOOCHOW UNIVERSITY   (China)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

5 FU; Chemoresistance; Hepatocellular carcinoma; PMSB7; PRDX6

Indexed keywords

FLUOROURACIL; HEAT SHOCK PROTEIN 27; MASPIN; MYL6 PROTEIN; PHB PROTEIN; PRDX6 PROTEIN; PROTEIN P16; PSMB7 PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; PRIMER DNA; TUMOR PROTEIN;

ARTICLE; CANCER CHEMOTHERAPY; DOWN REGULATION; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; IMAGE ANALYSIS; LIVER CELL CARCINOMA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; WESTERN BLOTTING; DRUG RESISTANCE; LIVER TUMOR; MASS SPECTROMETRY; METABOLISM; NUCLEOTIDE SEQUENCE; TUMOR CELL LINE;

ANTIMETABOLITES, ANTINEOPLASTIC; BASE SEQUENCE; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DNA PRIMERS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; NEOPLASM PROTEINS; PROTEOMICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84907028231     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161282001140113125143     Document Type: Article

References (25)

1. Ferlay J, Shin H R, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
3. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62: 220-41.
4. McCarthy N. Drug resistance: Time for mediation? Nat Rev Cancer 2012.
5. Longley D B, Harkin D P, Johnston P G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330-8.
6. Lee J S, Kim J H, Park Y Y, Mills G B. Systems biology approaches to decoding the genome of liver cancer. Cancer Res Treat 2011; 43: 205-11.
7. Kim S Y, Lee P Y, Shin H J, et al. Proteomic analysis of liver tissue from HBx-transgenic mice at early stages of hepatocarcinogenesis. Proteomics 2009; 9: 5056-66.
8. Wang Z, Zhang Y, Li Y, et al. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther 2006; 5: 483-93.
9. Tan Y, Ma S Y, Wang F Q, et al. Proteomic-based analysis for identification of potential serum biomarkers in gallbladder cancer. Oncol Rep 2011; 26: 853-9.
10. Xia J, Li Y, Yang Q, et al. Arsenic Trioxide Inhibits Cell Growth and Induces Apoptosis through Inactivation of Notch Signaling Pathway in Breast Cancer. Int J Mol Sci 2012; 13: 9627-41.
11. Wu Q, Qin S K, Teng F M, Chen C J, Wang R. Lobaplatin arrests cell cycle progression in human hepatocellular carcinoma cells. J Hematol Oncol 2010; 3: 43.
12. Wang Z, Banerjee S, Li Y, et al. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res 2006; 66: 2778-84.
13. Munkacsy G, Abdul-Ghani R, Mihaly Z, et al. PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer. Br J Cancer 2010; 102: 361-8.
14. Pak J H, Choi W H, Lee H M, et al. Peroxiredoxin 6 overexpression attenuates cisplatin-induced apoptosis in human ovarian cancer cells. Cancer Invest 2011; 29: 21-8.
15. Cen L, Carlson B L, Schroeder M A, et al. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro Oncol 2012; 14: 870-81.
16. Katsumi Y, Iehara T, Miyachi M, et al. Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression. Biochem Biophys Res Commun 2011; 413: 62-8.
17. Arima Y, Hayashi N, Hayashi H, et al. Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor-negative breast cancer. Int J Cancer 2012; 130: 2568-79.
18. Gallagher S J, Thompson J F, Indsto J, et al. p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors. Neoplasia 2008; 10: 1231-9.
19. Yu Y, Zhang Y, Hu J, et al. MARVELD1 inhibited cell proliferation and enhance chemosensitivity via increasing expression of p53 and p16 in hepatocellular carcinoma. Cancer Sci 2012; 103: 716-22.
20. Bodenstine T M, Seftor R E, Khalkhali-Ellis Z, et al. Maspin: molecular mechanisms and therapeutic implications. Cancer Metastasis Rev 2012; 31: 529-51.
21. Ben Shachar B, Feldstein O, Hacohen D, Ginsberg D. The tumor suppressor maspin mediates E2F1-induced sensitivity of cancer cells to chemotherapy. Mol Cancer Res 2010; 8: 363-72.
22. Lei K F, Liu B Y, Jin X L, et al. Prognostic value of nuclear maspin expression for adjuvant 5-fluorouracil-based chemotherapy in advanced gastric cancer. Exp Ther Med 2012; 3: 993-8.
23. Gurzu S, Szentirmay Z, Toth E, Jung I. Possible Predictive Value of Maspin Expression in Colorectal Cancer. Recent Pat Anticancer Drug Discov 2012.
24. Walsh B, Pearl A, Suchy S, et al. Overexpression of Prdx6 and resistance to peroxide-induced death in Hepa1-6 cells: Prdx suppression increases apoptosis. Redox Rep 2009; 14: 275-84.
25. Kalinina E V, Berezov T T, Shtil A A, et al. Expression of Peroxiredoxin 1, 2, 3, and 6 Genes in Cancer Cells during Drug Resistance Formation. Bull Exp Biol Med 2012; 153: 878-81.